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Abstract  
Aims  
To evaluate evaluate the benefits of adding insulin therapy, or switching to insulin,real world 
outcomes in type 2 diabetes (T2DM) patients treated with Glucagon-like peptide-1 Receptor 
Agonist (GLP-1RA) with inadequately controlled hyperglycaemia.  of adding or switching to 
insulin therapy in patients with type 2 diabetes (T2DM) with inadequately controlled 
hyperglycaemia treated with Glucagon-like peptide-1 Receptor Agonist (GLP-1RA)patients 
who failed to control HbA1cwith sub-optimal control of hyperglycaemia with Glucagon-like 
peptide-1 Receptor Agonist (GLP-1RA) treatment.   
 
Materials and Methods  
T2DM patients (n=66,583) with minimum 6 months of GLP-1RA treatment, without 
previous insulin treatment were selected. Those who added insulin (n=39,599) and thoseor 
switched to insulin upon GLP-1RA cessation (n=4,706) were identified. Adjusted changes in 
HbA1c, weight, systolic blood pressure (SBP), and LDL-C were estimated over 24 months’ 
follow-up. 
Results 
Among those who continued with GLP-1RA treatment without adding or switching to 
insulin, the highest adjusted mean HbA1c change was achieved within six months, with no 
further glycaemic benefits observed during 24 months follow-up. at 12 months. Patients who 
did not added/ or switched to insulin, reduced HbA1c by 0.73% (from the baseline 8.2%) at 6 
months, with no further glycaemic benefits during 24 months follow-up. Addition/switch to 
insulin therapy occurred at median 3/14 months of follow-up at mean HbA1c of 8.8/9.3%. 
Addingition of insulin within 6 months of GLP-1RA initiation was associated with 18% 
Page 2 of 27
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
3 
 
higher odds to achieve HbA1c<7% at 24 months, compared to adding insulin later. At 24 
months, those who added insulin reduced HbA1c significantly by 0.55%, while no glycaemic 
benefit was observed in those who moving switchinged to insulin did not yield any glycaemic 
benefit.  Irrespective of intensification with insulin, weight, SBP, and LDL-C were 
significantly reduced by 3 kg, 3 mmHg, and 0.2 mmol/L, respectively, over 24 months.   
 
Conclusions 
Significant delay in intensifying intensification of treatment by addition of GLP-1RA 
treatment with insulin was is observed in patients with T2DMType 2 diabetes inadequately 
controlled with GLP-1RAwith elevated HbA1c. Earlier addition of insulin resulted isa 
associated with in better glucose glycaemic control, while switching to insulin iwas not 
clinically beneficial during 2 years of treatment. Non-responding patients on GLP-1RA 
would benefit by adding insulin therapy, rather than switching to insulin.   
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Introduction 
People with diabetes are at increased risk of developing disabling and life-threatening health 
problems, including microvascular and macrovascular complications [1, 2]. Good control of 
hyperglycaemia and the associated risk factors in type 2 diabetes (T2DM) has been shown to 
reduce  the risk of these complications [1, 3]. Thus anti-hyperglycaemic treatment strategies 
should ideally also address the management of cardiovascular risk factors, including body 
weight, blood pressure (BP) and lipids [4]. Novel anti-hyperglycaemic Glucagon-like 
peptide–1 receptor agonist (GLP-1RA) therapies, including Exenatide and Liraglutide, have 
the potential to address these challenges [5-9].  
The combination of GLP-1RA and insulin treatments represents a promising glycaemic 
management strategy due to the complementary mechanisms of actions of these therapies 
[10]. Both therapies affect body weight, but in opposite directions: while significant weight 
reductions have been observed in patients treated with GLP-1RA, insulin is known to 
significantly increase body weight [11, 12]. A meta-analysis of clinical trials conducted by 
Eng and colleagues showed that the combination of GLP-1RA with basal insulin resulted in 
robust glycaemic control without increased risk of hypoglycaemia or weight gain  [13]. A 
number of observational and real-world data based studies have also evaluated the The 
effectiveness of adding GLP-1RA to basal insulin therapy on glucose and weight control in 
patients with T2DM has also been evaluated in a number of observational and real-world data 
based studies [10, 14-20]. Thus, iThe intensification of basal insulin therapy with by addition 
of GLP-1RA, instead of rather than adding mealtime insulin, has been widely investigated 
and been shown as to be an attractive therapeutic option [13, 21], and is now recommended in 
international guidelines: “The available data now suggest that either a GLP-1 receptor agonist 
or prandial insulin could be used in this setting [in patients not achieving target HbA1c], with 
the former arguably safer, at least for short-term outcomes” [21]. .. 
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A significant number of patients treated with GLP1RA also intensify therapy by adding 
insulin, or switching to insulin therapy, primarily because of sub-optimal glycaemic 
failurecontrol. However, to the best of our knowledge, only three observational studies (n = 
44 to 432) have evaluated the effectiveness of adding insulin to GLP-1RA therapy [20]. 
HoweverMoreover, these studies did not explore the HbA1c trajectories over time to 
understand the longitudinal patterns of glycaemic failure. Furthermore, no real-world study, 
to the best of our knowledge, has explored the dynamics of changes in glycaemic and 
cardiovascular risk factors from the time of GLP-1RA initiation dynamics duringthrough  the 
transition phase of of addition adding or switching to insulin therapy from the time of GLP-
1RA initiation.  The real-world patterns of adding or switching to insulin therapy from initial 
GLP-1RA treatment are also not well understood. AFurther, amongst patients with sub-
optimal glycaemic control who intensify GLP-1RA therapy by addingtion of insulin because 
of sub-optimal glycaemic control, it is not known whether earlier intensification is beneficial 
for a sustainable glucose control.  is also not know  
From the time of initiation of GLP-1RA therapy in patients with T2DM, the aims of this 
longitudinal cohort study were to evaluate (1) changes in HbA1c, body weight, BP and LDL-
cholesterol (LDL-C) over 6-, 12-, and 24-months of follow-up, (2) possible benefits of adding 
or switching to insulin treatment, and (3) the likelihood of clinically meaningful HbA1c 
reduction in those who intensified GLP-1RA treatment with insulin earlier, compared to 
those who added insulin later.   
 
Materials and Methods 
Data Source 
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The CentricityTM Electronic Medical Record (CEMR) database was used for this study. 
CEMR represents a variety of ambulatory medical practices from 49 US states, including solo 
practitioners, community clinics, academic medical centres, and large integrated delivery 
networks. The CEMR database consists of over more than 35,000 physicians and other 
providers, of whom approximately 75% are primary care providers. The database has been 
extensively used for academic research worldwide [22-25]. 
The CEMR database contains detailed prescription information with dates of prescription, 
including All medications entered in the patient’s medication list are stored in the CEMR. In 
such a way it contains data on medication prescriptions within EMR network, and also 
information on medications that were purchased may be used over the counter or prescribed 
outside of the EMR network. MThe main medication information data set stores individual 
records in the form of start / stop dates, along with it also contains several specific (i.e. 
chaining) fields to track treatment adjustments and alterations over time. 
From more than 2.4 million patients with confirmed diagnosis of T2DM, a cohort of 134,268 
patients who received treatment with GLP-1RA from April 2005 to October 2014, was 
identified. The final study cohort of 66,583 patients was selected on the basis of the following 
criteria: (1) diagnosis of diabetes from January 1990, (2) age ≥ 18 years at the diagnosis of 
diabetes, (3) no insulin therapy prior to the initiation of GLP-1RA treatment, (4) no missing 
data on age, sex, HbA1c and body weight at GLP-1RA initiation, and (5) minimum six 
months of continuous treatment with GLP-1 RA from the first recorded prescription date.  
In the final study cohort, those treated with Exenatide (EXE) and those treated with 
Liraglutide (LIRA) were identified. Those who added insulin therapy to existing GLP-1RA 
treatment (GLP+INS), and those who switched to insulin therapy upon the cessation of GLP-
1RA treatment (GLP→INS), were identified by comparing insulin initiation dates and GLP-
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1RA cessation dates. Time to addition of / switch to insulin therapy was calculated as the 
time difference between GLP-1RA and insulin initiation dates. Insulin therapy was identified 
by any insulin regimen (basal, biphasic or , prandial)., andwith mostThe majority of the 
patients in the EXE group (94%) were treated with a twice daily Exenatide regimen.  
Demographic, clinical and laboratory information included age, sex, ethnicity, and 
longitudinal measures of body weight, body mass index (BMI), systolic and diastolic blood 
pressure (SBP and DBP), HbA1c, and lipids. The clinical Clinical and laboratory data at 
GLP-1RA treatment initiation (index date) were included on the basis of a three-month 
window, on or prior to index date. The followFollow-up clinical and laboratory measures 
were arranged longitudinally on the basis of non-overlapping six-monthly windows, which 
were defined progressively from the time of GLP-1RA treatment initiation.  Complete 
information on anti-hyperglycaemic agents, anti-hypertensive agents, cardio-protective 
medications (CPMs), weight-lowering and anti-depressant drugs was obtained along with 
dates of prescriptions. The CPMs included statins, angiotensin-converting enzyme inhibitors 
(ACE), and angiotensin II receptor blockers (ARB).  The status of different medications 
intake was defined by whether it was taken during GLP-1RA treatment, and the treatment 
durations with such these medications were estimated. 
Statistical Methods 
While complete data on HbA1c and body weight were available at index date (by design), the 
The proportions of patients with missing longitudinal data on body weight, SBP, LDL-C and 
HbA1c between 6 and 24over  24 months of follow-up ranged between from 9% and to 19%. 
The missing longitudinal follow-up data were imputed using the multiple imputation 
techniqueapproach, with adjustments for age at index date and usage of oral anti-
hyperglycaemic drugs during follow-up. All primary analyses were conducted using the 
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imputed data, with additional analyses conducted for sensitivity assessment based on 
complete cases for sensitivity assessment.  
The mean (95% CI) of changes in HbA1c, body weight, SBP and LDL-C at 6-, 12-, and 24-
months from index date were estimated using multivariate regression models. The changes in 
the risk Risk factors changes were adjusted for age at index date, sex, ethnicity, and 
concomitant anti-hyperglycaemic, anti-hypertensive and weight lowering treatments, 
weighted by the respective baseline measures,  (as appropriate). Separate analyses for HbA1c 
and weight changes were conducted for patients who continued to receive only GLP-1RA 
treatment over 6-, 12-, and 24- months, and for those who added or switched to insulin during 
follow-up.  Robust estimates of the confidence intervals were obtained.  
For patients with HbA1c above 7.5% at the time of GLP-1RA initiation, the proportions of 
patients who achieved HbA1c below 7% at 6-, 12-, and 24- months of treatment were 
evaluated for all groups. Proportions of those who achieved weight loss greater than or equal 
to 5% from initial body weight at 6-, 12-, and 24- months post GLP-1RA initiation were also 
calculated. The characteristics of the patients who added or switched to insulin were 
presented at the index date and at the time of transition to insulin.  
Results 
In the cohort of 66,583 patients with minimum six months of treatment with GLP-1RA, mean 
(SD) age was 56 (11) years, 28,959 (43%) were male, 45,291 (68%) were White Caucasians, 
51,719 (87%) were obese, 3,404 (26%) / 858 (7%) had micro-/macro-albuminuria, and 
17,415 (26%) had a history of hypertension at the time of initiation of GLP-1RA treatment 
initiation (Table 1). The use of different medications during GLP-1RA therapy, along with 
their durations of treatment, are presented in Table 1.  
Glycaemic Control 
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With mean HbA1c of 8.2% at index date, among those who continued with GLP-1RA 
treatment without adding or switching to insulin, the highest adjusted mean HbA1c change 
was achieved within six months (-0.73%; CI: -0.73, -0.71), with no further glycaemic benefits 
at 12 months (-0.65%; CI: -0.65, -0.62) and or 24 months of follow-up (-0.59%;, CI: -0.60, -
0.58; Table 2; , Figure 1A), all p<0.01.  Among patients with HbA1c ≥ 7.5% at index date(n= 
), who did not add or switch to insulin, and who continued with GLP-1RA treatment only for 
12 and 24 months (n=14,682 and 6,825), 26% achieved HbA1c levels below 7% at 12 and 24 
months respectively (Table 2).   
Among those who added insulin during follow-up (GLP+INS, n=39,599), the mean HbA1c 
values at index date and at the time of adding insulin were 8.3% and 8.8% respectively. The 
median time to intensification with insulin was 3 months. Among these patients, those who 
had HbA1c above 7.5% and 8% at insulin initiation were 84% and 71% had HbA1c above 
7.5% and 8% at insulin initiation respectively. Those who added insulin within six months of 
GLP-1RA initiation achieved significantly highergreater (p<0.001)the highest adjusted 
HbA1c reduction at 24 months of follow-up (-0.58%; CI: -0.61, -0.57), compared to those 
who added insulin after 12 months (-0.41%; CI: -0.43, -0.40;) (Figure 1A). Those who added 
insulin within six months of GLP-1RA initiation were 18% (odds ratio: 1.18; 95% CI: 1.09, 
1.28; p<0.001) more likely to achieve HbA1c below 7% at 24 months of follow-up, 
compared to those who added insulin treatment later.  
The six monthly trajectories (mean, 95% CI) of HbA1c levels for those who switched to 
insulin therapy within 24 months (n=2,483; mean time to insulin: 14 month; Table 3) are 
presented in Figure 1B. In these patients the mean HbA1c was increased to 9.3% at the time 
to switching to insulin from mean HbA1c of 8.5% at GLP1-RA initiation, and 80% of them 
had HbA1c above 8% at insulin initiation (Table 3). Notably, these patients did not achieve 
better glycaemic control at 24 months, compared to their glycaemic status at index date 
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(Figure 1 B and C). MeanwhileIn contrast, patients who hadadded added insulin added within 
24 months of follow-up (n=36,113; mean time to insulin: 3 month; Table 3) experienced 
significant HbA1c reduction of 0.55% (CI: 0.54, 0.57) at 24 months compared to the index 
date (Figure 1C). The adjusted mean (95 % CI) of change in HbA1c and body weight at 6-, 
12-, and 24- months post GLP-1RA initiation, for those who ceased GLP-1RA after 6 months 
of initiation and switched to insulin between 6-12, 12-18, and 18-24 months, are presented in 
Supplementary Table 1. 
Weight Change 
With a baseline body weight of 109 kg (Table 1), patients with a minimum 12 months of 
treatment with GLP-1RA reduced had their body weight significantly greater adjusted weight 
reduction (by adjusted mean reduction 2.5 kg (95% CI: 2.50, 2.51)), and 24% reduced their 
body weight by ≥ 5% (Table 4). Among those who did not add or switch to insulin, and who 
continued GLP-1RA treatment only (without addition or switch to insulin) for 24 months, the 
average weight reduction from index date was 3.31 kg (CI: 3.30, 3.32), and a third of patients 
achieved a weight loss of  ≥ 5%. Patients who hadadded added insulin added achieved 
marginally higher weight reduction (adjusted) at 12 months and 24 months (2.93 kg and 3.40 
kg respectively, Table 4), compared to those who did not add or switch  to insulin therapy 
(2.50 kg and 3.31 kg respectively, Table 4).  
Associations of glucose and weight loss  
Among patients with a minimum of 12 months of GLP-1RA treatment, 78% and 67% had 
reductions in HbA1c and body weight, respectively, from the index date, while 53% reduced 
both body weight and HbA1c achieved simultaneous reductions (similar between patients 
treated with LIRA Liraglutide and EXExenatide, Figure 1D). At 12 months of follow-up, 8 % 
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and 7% failed to reduce both HbA1c and weight in the EXEExenatide and LIRAiraglutide 
groups, respectively. 
Cardiovascular risk factors 
With a mean 129 mmHg SBP level at index date, only 24% had SBP ≥ 140 mmHg. The 
adjusted average reduction in SBP was about 3 mmHg consistently over 6-, 12-, and 24- 
months of follow-up, and was similar across EXE and LIRA groups (Table 1 and Table 4). 
Among those who switched to insulin, the mean SBP levels at index date, at the time of 
moving to insulin, and at 24 month of follow-up remained stable at 130 mmHg.   
In the study cohort 92% patients were on lipid lowering therapy. The average reduction in 
LDL-C was 0.18 mmol/L or greater consistently during 6-, 12-, and 24- months of follow-up 
(range of CI of reduction: 0.17 – 0.24 mmol/L ; Table 4), starting with a baseline LDL-C 
level of 2.43 mmol/L. Among patients who did not receive any statin (n= 15,949), mean 
reductions in LDL-C at 6-, 12-, and 24-months were 0.15 mmol/L, 0.14 mmol/L and 0.17 
mmol/L, respectively (all p <0.001).  Among those who switched to insulin, the mean LDL-C 
levels at index, at the time of moving to insulin, and at 24 month of follow-up were 2.47, 
2.42, and 2.38 mmol/L, respectively.    
Discussion 
This longitudinal  cohort study of 66,583 T2DM patients treated with GLP-1RA suggests 
that: (1) significant HbA1c reductions are may be obtained within six months from GLP-1RA 
treatment initiation, with no further glycaemic benefits likely over 24 months of follow-up; 
(2) earlier intensification with insulin therapy by six months (when added to GLP-1RA) is 
associated with 18% higher odds of lowering HbA1c below 7% within two years of 
treatment; and (3) adding insulin, rather than switching to it, is associated with significantly 
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lower glucose levels in a long-term outcome. We have also observed a clear indication of 
therapeutic inertia among patients who failed to respond to GLP-1RA therapy.  
This study presents real world evidence of significant reductions in HbA1c, body weight, 
SBP and LDL-C over two years of follow-up in patients treated with GLP-1RA. Initiation of 
It was observed that GLP-1RA treatment introduction at lower HbA1c levels was associated 
with better glucose control over two years of follow-up. The observed  and the . oObserved 
HbA1c reductions were consistent with previous findings [15-19]. While glycaemic 
achievements observed within 6 months of GLP-1RA treatment initiation in clinical trials 
were higher in clinical trials, it is well knownrecognised that the the effectiveness studies 
based on real world data generally provide lower estimates of glycaemic reduction or 
treatment effect(s) in general. The mean HbA1c reduction in patients treated with Liraglutide 
was marginally higher than those treated with Exenatide, although the proportions of patients 
who reduced HbA1c below 7% over 12 and 24 months of follow-up (ranging between from 
26% and to 28%) were similar between these two therapies.  
With initial response to GLP-1RA within 6 month of follow-up, patients who switched to 
insulin (by design after 6 months of GLP-1 RA treatment) experienced a significant rise in 
the glycaemic level at different points of follow-up, as evident from the Figure 1B. For 
example, those who switched to insulin within 18-24 months post index date, clearly 
experienced rising HbA1c levels consistently above 8% after 6 months of treatment with 
GLP-1RA. Furthermore, we observed that although switching to insulin prevented any 
further rise in HbA1c, no significant glycaemic reductions were achieved by the end of the 24 
months follow-up period, compared to the index date (Figure 1 B and C). However, in those 
who patients in whomaddedwho added insulin was added demonstrated significantly better 
glycaemic control by the end of the follow up period. After adjusting for the HbA1c levels at 
index date and at the time of insulin initiation, those who added insulin achieved a 
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significantly higher HbA1c reduction at 24 months by 0.48% (95% CI: 0.47, 0.50%), 
compared to those who switched to insulin (Figure 1 C).  
This study revealed that addition of insulin and , or and switch to insulin occurs occurred at 
elevated HbA1c levels of 8.8% and 9.3% respectively, with a significant proportion of 
patients having HbA1c above 8 / 8.5% (71 / 58% in GLP+INS group and 80 / 68% in / 
GLP→INS group). This clearly brings upraises the issues of therapeutic inertia [26, 27]. 
Given the high glycaemic burden in this population, the time to intensification of therapy 
requires further evaluation −-  in conjunction with the factors that might prevent early 
intensification with insulin therapy, including fear of weight gain and hypoglycaemia. 
Notably, the distributions of body weight were similar between those who switched to, or 
added, insulin, and those who remained on GLP-1RA treatment only (Table 1). Moreover, 
observed adjusted weight reductions in patients who added insulin, were consistently and 
marginally greater than in those treated with GLP-1RA only during the follow-up period 
(Table 4). Our findings in terms of weight loss is consistent with a recent study reporting no 
weight gain post initiation of insulin in obese patients with T2DM [28] and the systematic 
review by Balena and colleagues [20]. 
The limitations of this study include non-availability of complete and reliable data on: (1) 
medication adherence; (2) dose adjustments in insulin treated patients; (32) diet and exercise; 
(43) socio-economic status; and (54) potential residual confounders.  The selection of patients 
with minimum 6 months treatment with GLP-1RA, excluding those who initiated insulin 
therapy earlier, could lead to a potential selection bias. However, the large analysis cohort 
from the validated CEMR database used in our study should be considered as a representative 
sample, and as such, provides a reliable picture of the state of risk factor management in 
routine practice. Complete risk factor data were available at index date, and imputations were 
conducted for only 9% to 19% missing longitudinal data. The results from complete case 
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analyses and imputed data were very similar. Finally, careful new-user design with a 
reasonable exposure time of two years, and appropriate adjustments for confounders are the 
primary strengths of the study.  
In conclusion, this novel real world study provides evidence of significant delays in 
intensification of treatment in T2DM patients treated with GLP-1RA. Among HbA1c non-
responders, early addition of insulin with GLP-1RA therapy within six months resulted in 
better and sustainable glycaemic control over two years. The findings from our study suggest 
that in people requiring treatment intensification on GLP-1RA, the preferred option should be 
addition of insulin rather than stopping GLP-1RA and switching to insulin therapy.   
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Table 1: Basic statistics on study parameters at the time of initiation of Exenatide or Liraglutide who continued GLP-1RA treatment for at-least six months, 
those who added insulin treatment during the follow-up, and those who switched to insulin treatment during the follow-up. The statistics are mean (SD) unless 
stated otherwise. 
 
ALL EXE LIRA GLP+INS GLP→INS 
N 66583 44523 22060 39599 4706 
Age at GLP-1RA Initiation 56 (11) 56 (11) 56 (11) 56 (11) 56 (11) 
Male
*
 28959 (43) 18917 (42) 10042 (46) 17531 (44) 2130 (45) 
Ethnicity: Caucasian
*
 45291 (68) 29500 (66) 15791 (72) 27231 (69) 3311 (70) 
Ethnicity: Black
*
 5021 (8) 3118 (7) 1903 (9) 2971 (8) 358 (8) 
Ethnicity: Hispanic
*
 1465 (2) 943 (2) 522 (2) 1023 (3) 89 (2) 
Ethnicity: Asian
*
 534 (1) 326 (1) 208 (1) 312 (1) 30 (1) 
HbA1c at Diagnosis of Diabetes, %  8 (1.4) 8 (1.4) 8.1 (1.5) 8.1 (1.5) 8.2 (1.5) 
HbA1c at GLP-1RA Initiation, %  8.2 (1.3) 8.1 (1.3) 8.3 (1.4) 8.3 (1.4) 8.4 (1.3) 
HbA1c at GLP-1RA Initiation, %
α 
 7.8 (7, 8.8) 7.8 (7, 8.7) 7.9 (7.1, 8.9) 8 (7.1, 9.0) 8.2 (7.4, 9.0) 
HbA1c ≥ 7% at GLP-1RA Initiation
*
 60351 (91) 40180 (90) 20171 (91) 36130 (91) 4388 (93) 
HbA1c ≥ 7.5% at GLP-1RA Initiation
*
 41045 (62) 26700 (60) 14345 (65) 25691 (65) 3388 (72) 
HbA1c ≥ 8% at GLP-1RA Initiation
*
 30599 (46) 19777 (44) 10822 (49) 19859 (50) 2628 (56) 
Weight at GLP-1RA Initiation, kg 109 (25) 110 (25) 109 (25) 110 (25) 108 (24) 
BMI at GLP-1RA Initiation, kg/m
2
 38 (8) 38 (8) 38 (8) 38 (8) 37 (8) 
Obese at GLP-1RA Initiation
*
 57927 (87) 38753 (87) 18971 (86) 34847 (88) 4000 (85) 
SBP at GLP-1RA Initiation, mmHg 129 (16) 129 (16) 129 (16) 129 (16) 130 (16) 
SBP ≥ 140 mmHg at GLP-1RA Initiation
*
 15728 (24) 10628 (24) 5100 (23) 9487 (24) 1184 (25) 
DBP at GLP-1RA Initiation, mmHg 77 (10) 77 (10) 77 (10) 77 (10) 77 (10) 
LDL-C at GLP-1RA Initiation, mmol/L 2.43 (0.72) 2.44 (0.73) 2.42 (0.72) 2.42 (0.74) 2.47 (0.74) 
LDL-C ≥ 3.37 mmol/L at GLP-1RA Initiation
*
 5780 (9) 3951 (9) 1829 (8) 3652 (9) 450 (10) 
HDL-C at GLP-1RA Initiation, mmol/L 1.10 (0.31) 1.11 (0.30) 1.10 (0.31) 1.10 (0.30) 1.09 (0.29) 
Triglyceride at GLP-1RA Initiation, mmol/L
α
 1.69 (1.23, 2.28) 1.69 (1.23, 2.27) 1.71 (1.24, 2.31) 1.71 (1.24, 2.29) 1.75 (1.25, 2.35) 
Triglyceride ≥ 1.69 mmol/L at GLP-1RA Initiation* 15060 (51) 9920 (50) 5140 (51) 10107 (51) 967 (53) 
Micro-albuminuria
*
 3404 (26) 2126 (25) 1278 (29) 2481 (26) 167 (26) 
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Macro-albuminuria
*
 858 (7) 532 (6) 326 (7) 597 (6) 49 (8) 
Hypertension
*
 17415 (26) 12707 (29) 4708 (21) 11020 (28) 1340 (28) 
Metformin taken during the GLP-1RA Treatment
*
 56035 (84) 37645 (85) 18390 (83) 33837 (85) 4129 (88) 
Metformin Duration, month
α
 52.7 (28.2, 84.3) 62.6 (34.9, 91.9) 36.6 (20.8, 61.1) 55.9 (30.3, 87.5) 71.8 (43.6, 97.6) 
Sulfonylurea taken during the GLP-1RA Treatment
*
 38003 (57) 26719 (60) 11284 (51) 23723 (60) 3583 (76) 
Sulfonylurea Duration, month
α
 32.5 (15, 60.3) 36.8 (17, 66) 25.4 (12.2, 45.8) 33.5 (15.2, 61.9) 39.8 (20.2, 67.9) 
Antihypertensive taken during the GLP-1RA Treatment
*
 53821 (81) 36610 (82) 17211 (78) 32655 (82) 4032 (86) 
Antihypertensive Duration, month
 α
 46.5 (23.8, 80.1) 54.7 (28.4, 86.9) 33.2 (17.5, 59.8) 48.7 (25.2, 82.3) 61.4 (33.9, 91.8) 
CPM taken during the GLP-1RA Treatment
*
 61145 (92) 41273 (93) 19872 (90) 36861 (93) 4462 (95) 
CPM Duration, month
α
 51.1 (26.6, 84.9) 59.9 (32.7, 91.6) 35.7 (19.4, 64.5) 53.8 (28.5, 87.5) 68.3 (39, 96.3) 
Weight lowering taken during the GLP-1RA Treatment
*
 4591 (7) 3297 (7) 1294 (6) 2831 (7) 328 (7) 
Weight lowering Duration, month
α
 12.6 (5.1, 28.2) 13.1 (5.2, 29.4) 11.9 (4.9, 25.5) 12.1 (4.8, 27.5) 12.6 (5.3, 28.7) 
Anti-depressants taken during the GLP-1RA Treatment
*
 28133 (42) 19865 (45) 8268 (37) 16950 (43) 2296 (49) 
Anti-depressants Duration, month
α
 35.6 (15.4, 68.6) 40.6 (17.4, 74.7) 27.2 (12.6, 51.4) 36.2 (15.5, 70.1) 43.4 (19.5, 78.9) 
*
N (%); 
α
Median (IQR); CPM: Cardio-protective medication (statins, angiotensin-converting enzyme inhibitors, or angiotensin II receptor blockers) 
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Table 2: Adjusted mean (95 % CI) of change in HbA1c at 6-, 12-, and 24- months post GLP-1RA initiation, for those who took GLP-1RA for at least 6-, 12-, 
and 24-months, by whether patients continued on GLP-1RA treatment only or added insulin therapy. For patients with HbA1c above 7.5% at GLP-1RA 
initiation, n (%) of those whose HbA1c reduced below 7%  at 6-, 12-, and 24- months post GLP-1RA initiation by whether patients took GLP-1RA only or 
added insulin therapy. 
  On GLP-1RA for ≥ 6 months On GLP-1RA for ≥ 12 months On GLP-1RA for ≥ 24 months 
  ALL EXE LIRA ALL EXE LIRA ALL EXE LIRA 
 66583 44523 22060 50109 35085 15024 28422 22111 6311 
∆ HbA1c at 6 months 
GLP-1RA only 
-0.73  
(-0.73, -0.71) 
-0.70  
(-0.71, -0.70) 
-0.80  
(-0.80, -0.79) 
-0.75  
(-0.76, -0.75) 
-0.72  
(-0.73, -0.72) 
-0.83  
(-0.81, -0.83) 
-0.75  
(-0.75, -0.74) 
-0.73  
(-0.73, -0.72) 
-0.85  
(-0.86, -0.85) 
GLP-1RA + INS 
-0.83  
(-0.84, -0.83) 
-0.75 
 (-0.77, -0.75) 
-0.95 
(-0.96, -0.94) 
-0.82  
(-0.82, -0.81) 
-0.75  
(-0.76, -0.75) 
-0.95  
(-0.96, -0.95) 
-0.81  
(-0.81, -0.80) 
-0.77  
(-0.77, -0.76) 
-0.93  
(-0.93, -0.92) 
HbA1c < 7% at 6 months for those whose HbA1c were ≥7.5% at GLP-1RA initiation 
GLP-1RA only 5410 (25) 3672 (24) 1738 (27) 3965 (27) 2826 (26) 1139 (29) 2018 (30) 1603 (29) 415 (34) 
GLP-1RA + INS 4156 (21) 2236 (19) 1920 (24) 3451 (22) 1987 (20) 1464 (25) 2338 (24) 1594 (22) 744 (28) 
∆ HbA1c at 12 months 
GLP-1RA only - - - 
-0.65  
(-0.65, -0.62) 
-0.62  
(-0.62, -0.61) 
-0.71  
(-0.72, -0.71) 
-0.67  
(-0.68, -0.67) 
-0.65  
(-0.67, -0.65) 
-0.74  
(-0.74, -0.72) 
 GLP-1RA + INS - - - 
-0.73  
(-0.73, -0.72) 
-0.67  
(-0.67, -0.66) 
-0.85  
(-0.86, -0.85) 
-0.74  
(-0.75, -0.74) 
-0.71  
(-0.71, -0.70) 
-0.84  
(-0.84, -0.83) 
HbA1c < 7% at 12 months for those whose HbA1c were ≥7.5% at GLP-1RA initiation  
GLP-1RA only - - - 3829 (26) 2770 (26) 1059 (27) 1960 (29) 1577 (28) 383 (32) 
GLP-1RA + INS - - - 3462 (22) 2083 (21) 1379 (24) 2401 (24) 1679 (23) 722 (27) 
∆ HbA1c at 24 months 
GLP-1RA only - - - - - - 
-0.59  
(-0.60, -0.58) 
-0.58  
(-0.58, -0.57) 
-0.63  
(-0.64, -0.63) 
GLP-1RA + INS - - - - - - -0.65  -0.63  -0.70  
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(-0.66, -0.65) (-0.64, -0.63) (-0.71, -0.70) 
HbA1c < 7% at 24 months for those whose HbA1c were ≥7.5% at GLP-1RA initiation  
GLP-1RA only - - - - - - 1806 (26) 1469 (26) 337 (28) 
GLP-1RA + INS - - - - - - 2247 (23) 1621 (23) 626 (23) 
 
 
Page 21 of 27
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
22 
 
Table 3: HbA1c levels at GLP-1RA initiation and at insulin initiation, and the time to insulin therapy, for those who added insulin to existing GLP-1RA 
(GLP+INS) and those who switched to insulin treatment (GLPINS) within two years of follow-up. Statistics are mean (SD) unless stated otherwise. 
 GLP+INS GLP→INS 
 
ALL EXE LIRA ALL EXE LIRA 
N 36113 22703 13410 2483 1856 627 
HbA1c at GLP-1RA Initiation, %  8.3 (1.4)  8.3 (1.4)  8.4 (1.4)  8.5 (1.4)  8.5 (1.4)  8.5 (1.4)  
HbA1c at GLP-1RA Initiation, %
α
 8 (7.1, 9)  7.9 (7.1, 9)  8.1 (7.2, 9.1)  8.3 (7.5, 9.2)  8.3 (7.5, 9.2)  8.3 (7.6, 9.3)  
HbA1c >= 7% at GLP-1RA Initiation
*
 33032 (91) 20649 (91) 12383 (92) 2351 (95) 1761 (95) 590 (94) 
HbA1c >= 7.5% at GLP-1RA Initiation
*
 23736 (66) 14507 (64) 9229 (69) 1892 (76) 1404 (76) 488 (78) 
HbA1c >= 8% at GLP-1RA Initiation
*
 18436 (51) 11202 (49) 7234 (54) 1489 (60) 1119 (60) 370 (59) 
HbA1c at Insulin Initiation, %  8.8 (1.3)  8.8 (1.3)  8.8 (1.3)  9.3 (1.6) 9.2 (1.5) 9.5 (1.7)  
HbA1c at Insulin Initiation, % 
α
 8.7 (7.8, 9.4)  8.7 (7.8, 9.4)  8.8 (7.9, 9.5)  9.1 (8.2, 10)  9 (8.1, 10)  9.1 (8.4, 10.3)  
HbA1c >= 7% at Insulin Initiation
*
 36045 (100) 22652 (100) 13393 (100) 2482 (100) 1855 (100) 627 (100) 
HbA1c >= 7.5% at Insulin Initiation
*
 30267 (84) 18848 (83) 11419 (85) 2209 (89) 1634 (88) 575 (92) 
HbA1c >= 8% at Insulin Initiation
*
 25649 (71) 15897 (70) 9752 (73) 1985 (80) 1466 (79) 519 (83) 
∆ HbA1c (Insulin - GLP-1RA), %
α
 0.46 (0.45, 0.47) 0.49 (0.47, 0.50) 0.42 (0.4, 0.44) 0.73 (0.67, 0.79) 0.67 (0.60, 0.73) 0.91 (0.80, 1.03) 
Time to Insulin Initiation, month
β
 3 (0, 24) 3 (0, 24) 2 (0, 24) 14 (6, 24) 14 (6, 24) 14 (6, 24) 
Time to Insulin Initiation, month
α
 0 (0, 3) 0 (0, 4) 0 (0, 2) 13 (10, 18) 14 (10, 19) 12 (9, 18) 
*
N (%); 
α
Median (IQR); 
β
Mean (Range) 
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Table 4: Adjusted mean (95 % CI) of change in body weight at 6-, 12-, and 24- months post GLP-1RA initiation, for those who took GLP-1RA for at least 6-, 
12-, and 24-months, by whether patients continued on GLP-1RA treatment only or added insulin therapy. n (%) of those who lost 5% or more of body weight 
during follow-up from GLP-1RA initiation. Adjusted mean (95 % CI) of changes in SBP and LDL-C at 6-, 12-, and 24- months post GLP-1RA initiation. 
  On GLP-1RA for ≥ 6 months On GLP-1RA for ≥ 12 months On GLP-1RA for ≥ 24 months 
 ALL EXE LIRA ALL EXE LIRA ALL EXE LIRA 
∆ Weight at 6 months 
GLP-1RA only 
-1.87 (-1.88, 
-1.87) 
-1.90 (-1.91, 
-1.90) 
-1.80 (-1.81, 
-1.80) 
-1.96 (-1.97, 
-1.96) 
-2.00 (-2.00, 
-1.99) 
-1.86 (-1.87, 
-1.85) 
-2.24 (-2.24, 
-2.23) 
-2.23 (-2.24, 
-2.23) 
-2.25 (-2.26, 
-2.23) 
GLP-1RA + 
INS 
-2.32 (-2.32, 
-2.31) 
-2.20 (-2.20, 
-2.19) 
-2.51 (-2.52, 
-2.51) 
-2.41 (-2.41, 
-2.40) 
-2.26 (-2.26, 
-2.25) 
-2.68 (-2.68, 
-2.67) 
-2.50 (-2.50, 
-2.49) 
-2.38 (-2.39, 
-2.37) 
-2.84 (-2.85, 
-2.83) 
Weight loss ≥5% at 6 months  
GLP-1RA only 5539 (15) 3957 (15) 1582 (15) 3978 (15) 2980 (15) 998 (15) 2050 (16) 1684 (16) 366 (17) 
GLP-1RA + 
INS 
5241 (18) 3085 (17) 2156 (19) 4413 (18) 2729 (17) 1684 (20) 2985 (19) 2124 (18) 861 (21) 
∆ Weight at 12 months 
 GLP-1RA only - - - 
-2.50(-2.51, -
2.50) 
-2.54 (-2.55, 
-2.54) 
-2.39 (-2.39, 
-2.38) 
-2.83 (-2.84, 
-2.82) 
-2.82 (-2.83, 
-2.82) 
-2.87 (-2.88, 
-2.85) 
GLP-1RA + 
INS 
- - - 
-2.93 (-2.93, 
-2.92) 
-2.80 (-2.81, 
-2.80) 
-3.16 (-3.16, 
-3.15) 
-3.08 (-3.08, 
-3.07) 
-3.00 (-3.00, 
-2.99) 
-3.31 (-3.32, 
-3.30) 
Weight loss ≥ 5% at 12 months 
GLP-1RA only - - - 6150 (24) 4644 (24) 1506 (23) 3204 (25) 2662 (26) 542 (25) 
GLP-1RA + 
INS 
- - - 
6404 (26) 4062 (26) 2342 (28) 4314 (27) 3132 (27) 1182 (29) 
∆ Weight at 24 months 
 GLP-1RA only - - - - - - -3.31 (-3.32, -3.3 (-3.31, - -3.36 (-3.38, 
Page 23 of 27
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
24 
 
-3.30) 3.29) -3.35) 
 GLP-1RA + 
INS 
- - - - - - 
-3.40 (-3.41, 
-3.40) 
-3.32 (-3.33, 
-3.31) 
-3.63 (-3.64, 
-3.62) 
Weight loss ≥ 5% at 24 months  
GLP-1RA only - - - - - - 3884 (31) 3210 (31) 674 (31) 
GLP-1RA + 
INS 
- - - - - - 
5104 (32) 3747 (32) 1357 (33) 
Blood pressure changes 
∆ SBP at 6 
months 
-2.82 (-2.82, 
-2.81) 
-2.78 (-2.78, 
-2.77) 
-2.90 (-2.91, 
-2.89) 
-2.95 (-2.96, 
-2.95) 
-2.91 (-2.91, 
-2.90) 
-3.05 (-3.06, 
-3.04) 
-2.91 (-2.91, 
-2.90) 
-2.87 (-2.87, 
-2.86) 
-3.05 (-3.07, 
-3.04) 
∆ SBP at 12 
months 
- - - 
-2.79 (-2.79, 
-2.78) 
-2.79 (-2.79, 
-2.78) 
-2.79 (-2.80, 
-2.78) 
-2.85 (-2.86, 
-2.85) 
-2.78 (-2.78, 
-2.77) 
-3.13 (-3.14, 
-3.11) 
∆ SBP at 24 
months 
- - - - - - 
-2.64 (-2.64, 
-2.63) 
-2.69 (-2.70, 
-2.69) 
-2.44 (-2.46, 
-2.42) 
LDL changes 
∆ LDL-C at 6 
months 
-0.19 (-0.20, 
-0.19) 
-0.19 (-0.20, 
-0.19) 
-0.19 (-0.19, 
-0.18) 
-0.19 (-0.19, 
-0.18) 
-0.19 (-0.20, 
-0.19) 
-0.19 (-0.19, 
-0.18) 
-0.19 (-0.21, 
-0.18) 
-0.18 (-0.18, 
-0.17) 
-0.20 (-0.21, 
-0.19) 
∆ LDL-C at 12 
months 
- - - -0.18 (-0.19, 
-0.18) 
-0.18 (-0.19, 
-0.18) 
-0.19 (-0.19, 
-0.18) 
-0.19 (-0.20, 
-0.19) 
-0.18 (-0.18, 
-0.17) 
-0.20 (-0.21, 
-0.18) 
∆ LDL-C at 24 
months 
- - - - - - -0.23 (-0.24, 
-0.23) 
-0.23 (-0.24, 
-0.23) 
-0.23 (-0.23, 
-0.22) 
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Figure Legend 
Figure 1: (A) Mean (95% CI) of longitudinal HbA1c measurements by whether patient added insulin within 6 / 6-12 / 12-18 / 18-24 months from the GLP-
1RA initiation, or remained on GLP-1RA treatment only; (B)  Mean (95% CI) of longitudinal HbA1c measurements by whether patient switched to insulin 
within 6-12 / 12-18 / 18-24 months from the GLP-1RA initiation; (C)  Mean (95% CI) of longitudinal HbA1c measurements by whether patient added or 
switched to insulin within 24 months from GLP-1RA initiation; (D) Scatterplot of HbA1c change and body weight change at 6 and 12 months for patients 
treated with Exenatide and Liraglutide without adding or switching to insulin. The perpendicular dotted lines present the mean time to addition or switching to 
insulin by categories of timeline. 
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Supplementary Table 1: Adjusted mean (95 % CI) of change in HbA1c and body weight at 6-, 12-, and 24- months post GLP-1RA initiation, for those who 
ceased GLP-1RA after 6 months of initiation and switched to insulin between 6-12, 12-18, and 18-24 months. 
 Switch to insulin within 6-12 months 
n= 1030 
Switch to insulin within 12-18 months 
n=776 
Switch to insulin within 18-24 months 
n=677 
∆ HbA1c at 6 months -0.45 (-0.46, -0.45) -0.50 (-0.50, -0.49) -0.49 (-0.50, -0.49) 
∆ HbA1c at 12 months -0.08 (-0.08, -0.07) -0.16 (-0.16, -0.15) -0.23 (-0.23, -0.22) 
∆ HbA1c at 24 months -0.46 (-0.46, -0.45) -0.24 (-0.25, -0.24) 0.18 (0.17, 0.18) 
∆ Weight at 6 months -1.68 (-1.72, -1.64) -1.32 (-1.32, -1.31) -1.73 (-1.76, -1.71) 
∆ Weight at 12 months -1.69 (-1.71, -1.67) -1.63 (-1.64, -1.62) -1.92 (-1.95, -1.90) 
∆ Weight at 24months -0.93 (-0.95, -0.91) -0.91 (-0.93, -0.89) -1.98 (-1.99, -1.97) 
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